Low business R&D a major threat to the European knowledge-based economy

European Commission presents a new publication on Europe's position in research and innovation. The "Key figures 2007 on Science, Technology and Innovation" shows that R&D intensity (R&D expenditure as % of GDP) in Europe has stagnated since the mid-nineties, while major competitors such as Japan, China or South Korea have been able to increase substantially their R&D effort, shaping a world where knowledge is more evenly distributed than ever before. Moreover, the R&D investment deficit against the US has remained constant over recent years. In particular, the low level of business R&D in the EU remains worrying. Key Figures 2007 shows that differences in the industrial structure of the EU compared to countries such as the US are the main cause for this low level of business R&D, with the EU having a smaller high-tech industrial sector, which usually has much higher levels of R&D spending. The new actions taken in Europe since 2005 in the context of the revised Lisbon Strategy need to be implemented if Europe is to successfully face this challenge.

"Knowledge is a key component of competitiveness" said European Science and Research Commissioner Janez Potočnik. "If our businesses are to be at the leading edge in the future, they need to invest in knowledge now. And governments need to put in place the appropriate measures to help them do so."

Since the last Key Figures in 2005, policy-makers have launched new initiatives at both EU and Member State level in order to boost the "Europe of Knowledge": The ambitious Seventh Framework Programme (FP7) has been adopted and is now underway with a substantially higher budget than its predecessor, FP6. Member States have made new and far-reaching commitments within the framework of the renewed Lisbon strategy by setting future R&D intensity targets. The recently published ERA Green Paper has launched a wide-ranging debate on the future orientations of the European Research Area (ERA).

Key Figures 2007 presents data and statistics on science, technology and innovation up to 2005, thus predating these recent initiatives and renewed commitments. It shows however that these recent policy developments are now more than ever needed, for at least five reasons:

  • The EU is part of a globalised world where knowledge is more evenly distributed than ever before. High competition on this level requires the EU to adapt and make the ERA more attractive to the rest of the world. The Key Figures 2007 show that countries like China already act as strong competitors in the globalised knowledge-based economy.
  • The report shows that EU R&D intensity has stagnated since the mid-nineties. In 2005, only 1.84% of GDP was spent on R&D in EU-27 and it still remains at a lower level than in the US, Japan or South Korea. Also new emerging economies such as China are rapidly catching-up. If current trends last, China will have caught up with the EU by 2009 in terms of R&D intensity. However, high R&D-intensive EU Member States such as Austria, Germany, Finland and Denmark show that it is possible to maintain and increase R&D intensity above 2% and even 3% of GDP.
  • Over 85% of the R&D intensity gap between the EU and its main competitors is caused by differences in business sector R&D financing. The low level of private R&D expenditure in Europe in comparison with the US is mostly due to differences in industrial structure and to the smaller size of the high-tech industry in the EU.
  • Regarding research excellence, although the EU is the world's largest producer of scientific knowledge, the impact of European science is lower than that of the US. Europe lags behind the US in all scientific disciplines in terms of citation impact scores and highly-cited publications. Also, EU universities are very much underrepresented at the top of a ranking based on bibliometric indicators of the world's largest universities. In addition, the linkage between technology (patented inventions) and the science base is much weaker in the EU than in the US. Europe has a difficulty in breaking through in new high-tech industries.
  • Even though private sector funds are a notable part of R&D, the public sector still has a major role to play. Public R&D funding in the EU must be sustained in order for private R&D activities to develop further and grow on a solid science base. The Key Figures 2007 reveal that high R&D intensity can be achieved when high contributions from the private sector go hand in hand with high levels of public funding. For those economies that are catching up, government funding of R&D is critical for creating and developing S&T capabilities.
For further information, please visit:
http://ec.europa.eu/invest-in-research/monitoring/statistical01_en.htm

Most Popular Now

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

A Novel AI-Based Method Reveals How Cell…

Researchers from Tel Aviv University have developed an innovative method that can help to understand better how cells behave in changing biological environments, such as those found within a cancerous...